Core Viewpoint - Beyond Meat's stock has plummeted to near $1 per share following a debt exchange deal that significantly dilutes existing shareholders, leading to a loss of over 99% in stock value since its peak in 2019 [1][2][3]. Company Summary - The company finalized a debt exchange deal where 97% of bondholders agreed to swap existing notes for new debt due in 2030, resulting in the issuance of approximately $208.7 million in new 7% convertible notes and up to 316 million new shares [3][4]. - Prior to the deal, Beyond Meat had 76.6 million shares outstanding, indicating a dilution of over 300% for existing investors if all bondholders convert their notes [4]. - The company's market capitalization has fallen to under $80 million, a stark contrast to the $3.8 billion valuation at its IPO six years ago [9]. Financial Performance - Revenue is projected to decline nearly 14% this year to about $281.6 million, with a 20% drop in revenue last quarter to $75 million due to decreased consumer interest in imitation meats [13]. - The company has withdrawn its annual sales targets after missing quarterly estimates, reflecting ongoing operational challenges and high manufacturing costs [13][18]. Market Reaction - Following the announcement of the debt exchange, there was a massive sell-off, with shares dropping almost 50% in one day and down more than 76% for the year [1][5]. - Analysts have expressed skepticism regarding the company's ability to stabilize sales or regain investor confidence, with TD Cowen lowering its target price from $2 to $0.80 and reaffirming a "Sell" rating [10][12]. Industry Context - The plant-based meat market has seen waning consumer interest, particularly in the U.S., leading to major restaurant chains scaling back on plant-based offerings [17]. - Competitors in the market, such as Maple Leaf Foods and Impossible Foods, have also faced challenges, including layoffs and restructuring efforts [17].

Key Points Tilray reported a surprise profit yesterday. The share price went up -- and Tilray cashed in by announcing a big share sale. 37.3 million Tilray shares could soon flood onto the market. 10 stocks we like better than Tilray Brands › Tilray Brands (NASDAQ: TLRY), the Canadian marijuana stock, closed 22% higher yesterday after reporting a surprise profit for fiscal Q1. That's the good news. The bad news is that Tilray wasted no time capitalizing on its new and improved stock price. No soo ...

Time for under 30. You're watching NextGen Investing here on the Schwab network. I'm Alex Coffee and I'm now joined by George Tillis, senior markets correspondent for the network.And George, we come back to a name we've discussed many of times. That's Joby Aviation. But it's almost a crossover to one of your other favorite discussion topics, which is these companies floating stock in some way or another and why that's a risk.So why don't you walk through why this stock's down, you know, 8% now, but even it ...

Joby Aviation Inc. (NYSE: JOBY) opened roughly 10% down on Wednesday after revealing plans of a major stock offering that it said will result in more than $500 million in gross proceeds. In its press ... ...

Key Points Joby sold $513 million of stock last night at a price of $16.85 per share. The offering price was 11% below where the stock closed yesterday. Joby's revenue is still negligible, meaning the company will have to raise money to fund its investments. 10 stocks we like better than Joby Aviation › Shares of Joby Aviation (NYSE: JOBY) were moving lower today after the maker of electric vertical takeoff and landing (eVTOL) vehicles held a follow-on stock offering last night. Investors tend t ...

Biomea Fusion Inc‘s (NASDAQ:BMEA) stock price plummeted after the company priced its public offering. The public offering includes 11.2 million shares of common stock and accompanying warrants to purchase an equal number of shares. Certain investors will receive pre-funded warrants for up to 1 million shares, with warrants to purchase an additional 1 million shares. The offering also includes a 30-day option for underwriters to purchase up to 1.83 million additional shares and warrants. The common stock and ...

Core Viewpoint - Wolfspeed's stock is experiencing a significant decline due to recent restructuring and stock dilution, impacting investor sentiment and stock value [1][2][4] Group 1: Stock Performance - Shares of Wolfspeed are down 12.1% as of 1:35 p.m. E.T., contrasting with modest gains in the S&P 500 and Nasdaq Composite [1] - The stock is falling as investors begin to understand the implications of the company's restructuring [2] Group 2: Restructuring and Dilution - Wolfspeed has exited Chapter 11 protection after restructuring, but this has led to severe dilution for common stockholders to satisfy creditors [2] - The company canceled all existing shares and issued new stock, with previous shareholders receiving approximately one share for every 120 shares they owned [3] Group 3: Investor Caution - Many investors were unaware of the dilution risks, leading to purchases at what appeared to be low prices [4] - Wolfspeed has indicated that equity holders may experience significant losses on their investments, highlighting the importance of understanding the fine print in such situations [4]

Key takeaway: Michael Saylor’s company, formerly known as MicroStrategy, now holds more Bitcoin than the cash reserves of several of the world’s largest tech giants. What happened Strategy Inc disclosed in a Sept. 8 filing that its Bitcoin holdings have reached 638,460 BTC, worth about $71 billion. This puts the company fifth among the world’s largest corporate treasuries, above Nvidia ($57B), Apple ($55B), Meta ($47B) and Tesla ($37B). Only Microsoft, Google, Amazon and Berkshire Hathaway sit higher on t ...

Group 1 - Iovance Biotherapeutics (IOVA) is conducting a secondary stock offering to raise $350 million, with share pricing yet to be disclosed [1][7] - The company's stock fell 6% following the announcement, reflecting investor concerns over potential dilution from the new issue [2][7] - Year-to-date, Iovance's shares have decreased by 66%, contrasting with a 4% growth in the industry [3] Group 2 - Proceeds from the stock offering will be used to expand the commercial reach of Iovance's melanoma therapy, Amtagvi, and support clinical development of pipeline candidates [5][9] - Iovance has two marketed drugs: Proleukin for metastatic renal cell carcinoma and metastatic melanoma, and Amtagvi, which is under evaluation in combination with Merck's Keytruda for advanced melanoma [6][8] - The company is on track to provide updates from various clinical studies, including the phase II IOV-LUN-202 study for post-anti-PD-1 non-small cell lung cancer and the phase II IOV-GM1-201 study for advanced melanoma [9][10]